List of Staxyn drug patents

Staxyn is owned by Bayer Hlthcare.

Staxyn contains Vardenafil Hydrochloride.

Staxyn has a total of 1 drug patent out of which 0 drug patents have expired.

Staxyn was authorised for market use on 17 June, 2010.

Staxyn is available in tablet, orally disintegrating;oral dosage forms.

The generics of Staxyn are possible to be released after 23 December, 2028.

STAXYN's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8613950 BAYER HLTHCARE Pharmaceutical forms with improved pharmacokinetic properties
Dec, 2028

(5 years from now)

Drugs and Companies using VARDENAFIL HYDROCHLORIDE ingredient

Market Authorisation Date: 17 June, 2010

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

How can I launch a generic of STAXYN before it's patent expiration?
More Information on Dosage

STAXYN family patents

3

United States

3

European Union

2

Malaysia

2

Russia

2

Costa Rica

2

Norway

2

Argentina

2

Peru

2

China

1

Portugal

1

Germany

1

Singapore

1

Uruguay

1

Guatemala

1

Spain

1

Brazil

1

Croatia

1

New Zealand

1

Dominican Republic

1

Austria

1

Mexico

1

Morocco

1

Taiwan, Province of China

1

Korea, Republic of

1

Hong Kong

1

Honduras

1

Tunisia

1

South Africa

1

Japan

1

Canada

1

Cyprus

1

Slovenia

1

Ukraine

1

Israel

1

Poland

1

Australia

1

RS

1

Denmark

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in